Pharmacological Treatment of Post-Herpetic Neuralgia (PHN)

First-Line Agents (Strongest Evidence)

1. α2δ Calcium Channel Ligands (Gabapentinoids)

• Gabapentin (immediate-release, extended-release, or gabapentin enacarbil): Indicated specifically for PHN management in adults. Titrated slowly to minimize somnolence; adequate analgesia may take 2–3 months. One RCT showed no benefit when added acutely during zoster to prevent PHN, but it is highly effective once PHN is established.
• Pregabalin: FDA-approved for PHN; provides more predictable pharmacokinetics than gabapentin. A 2024 model-based meta-analysis (PMID 38649099) comparing pregabalin to the novel agent mirogabalin found both had similar overall efficacy, but pregabalin has a faster onset (rate constant ~3× higher). Typical starting dose: 75 mg BID, titrating to 300 mg/day.

Fitzpatrick's Dermatology: "RCTs demonstrated efficacy for pain relief in PHN for gabapentin, pregabalin, tricyclic antidepressants, opioid analgesics, tramadol, 5% lidocaine patch, and high-concentration capsaicin patch."

2. Tricyclic Antidepressants (TCAs)

• Starting dose: ~25–50 mg at bedtime; may increase to 125 mg/day as needed.
• Particularly effective for constant burning pain and allodynia.
• Adams and Victor's Neurology notes: "In a number of controlled studies, amitriptyline proved to be an effective therapeutic measure."
• Nortriptyline (secondary amine): Comparable efficacy to amitriptyline with fewer anticholinergic side effects — preferred in elderly patients. One RCT showed combined nortriptyline + gabapentin reduced pain more than either agent alone (Dermatology 2-Volume Set 5e).
• Desipramine: Another secondary amine TCA used when anticholinergic effects are problematic.

Caution: Anticholinergic effects (urinary retention, confusion, constipation) often limit TCA use in the elderly — the very population most affected by PHN. Use with care in cardiac disease.

3. Topical Agents (High Efficacy, Minimal Systemic Effects)

Lidocaine 5% Patch (Lidoderm)

• FDA-approved for PHN; applied directly over the most painful area.
• Mechanism: reduces peripheral sensitization of nociceptors.
• Excellent tolerability — particularly suited for elderly or medically complex patients who cannot tolerate systemic drugs.
• Up to 3 patches simultaneously for up to 12 hours/day.

Capsaicin 8% Patch (Qutenza / Quenza)

• High-concentration capsaicin (8%) administered as a single 60-minute application by a healthcare provider.
• Depletes substance P from peripheral nociceptors; effect lasts approximately 3 months per application.
• Must be applied in a monitored clinical setting; EMLA cream applied 1 hour before reduces application-related burning pain (Morgan & Mikhail's Clinical Anesthesiology).
• Phase III RCTs confirm efficacy; particularly useful for patients who cannot tolerate oral medications.

Low-concentration topical capsaicin (0.025–0.075% cream, applied QID) provides modest benefit with significant application-site burning — less preferred than the 8% patch.

Second-Line / Adjunctive Agents

4. Opioid Analgesics

• Tramadol (weak µ-opioid agonist + SNRI): Validated by RCT for PHN. A useful option when gabapentinoids and TCAs fail.
• Oxycodone (controlled-release), Morphine, Hydromorphone: Strong opioids supported by RCT evidence for PHN. Reserved for moderate-to-severe pain not controlled by first-line agents.
• Risk of dependence, constipation, falls in elderly — use the lowest effective dose for the shortest duration.

5. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

• Duloxetine and Venlafaxine: Used as alternatives to TCAs when anticholinergic effects are unacceptable. Evidence is stronger for diabetic neuropathy but extended to PHN in many guidelines.

6. Other Anticonvulsants

• Carbamazepine and Valproate: Used as adjuncts, particularly for lancinating (shooting/electric) pain components. Adams and Victor's Neurology: "The addition of carbamazepine, gabapentin, pregabalin, valproate, or one of the serotonin reuptake inhibitor drugs may further moderate the pain, particularly if it is of lancinating type."

Combination Therapy

• Gabapentin + Nortriptyline: RCT-proven superiority over either drug alone.
• Gabapentin + Opioid: Evidence supports combination for inadequate responders.
• Topical lidocaine + oral agent: Additive benefit with no pharmacokinetic interactions.

Emerging & Investigational Agents (2023–2026 Evidence)

Interventional Options (Non-Drug But Evidence-Supported)

• Sympathetic nerve blocks (stellate ganglion or thoracic epidural): Most effective when initiated within 2 months of rash; up to 80% resolution in some series. Largely ineffective once PHN is well-established.
• Spinal cord stimulation (SCS): 2023 systematic review (PMID 37436342) supports SCS for refractory neuropathic pain with long-term efficacy.
• Epidural steroid injections: Not proven to prevent or treat established PHN.
• TENS (Transcutaneous Electrical Nerve Stimulation): May provide modest adjunctive benefit.

Treatment Decision Summary

Key principle: On average, first-line agents achieve adequate pain relief (≥50% reduction or pain < 3/10) in only 30–60% of patients — combination therapy and early pain clinic referral for refractory cases are essential (Fitzpatrick's Dermatology).

Prevention Remains the Best Strategy

• Shingrix (recombinant zoster vaccine): >90% efficacy against herpes zoster and PHN; strongly recommended for all immunocompetent adults ≥50 years. Dramatically reduces PHN incidence.
• Early antiviral therapy (acyclovir, valacyclovir, famciclovir within 72 hours of rash) reduces severity and duration of acute pain and may reduce PHN risk.

• Fitzpatrick's Dermatology, Treatment of PHN section
• Adams and Victor's Principles of Neurology, 12th Ed.
• Morgan & Mikhail's Clinical Anesthesiology, 7th Ed.
• Andrews' Diseases of the Skin
• Huerta et al. (2023). Investigational Drugs for PHN. Int J Mol Sci. PMID: 37629168
• Yu et al. (2026). Botulinum Toxin Type A for Neuralgia. Int J Med Sci. PMID: 41938503
• Hong et al. (2024). Mirogabalin vs Pregabalin for PHN. Eur J Pharm Sci. PMID: 38649099